All News

This has caused an ongoing problem with mistrust in many vaccines and medications, since there is still uncertainty surrounding how they affect other races and ethnicities.

In the fifth part of the series, students discussed the effects the pandemic had on their future career goals or prospects.

Specific infection-fighting cells of the immune system found to be downregulated, offering a potential clue to the cause of prolonged COVID-19 illness in children.

The FDA has granted orphan drug designation to CFT7455 for the treatment of multiple myeloma, according to a press release from manufacturer C4 Therapeutics.

The designation highlights the need for new treatment options for patients with platinum-resistant ovarian cancer and the significant treatment potential of IN10018, according to a press release from InxMed, the manufacturer of the novel drug.

An announcement from CDC officials recommending COVID-19 boosters for all adults could come as soon as this week, although doses would only be widely administered once the FDA formally approved the vaccines.

Ridinilazole is not currently approved for use by any regulatory authority.

Physicians may ask for either or both of comprehensive metabolic panel or complete blood count tests every 3 to 6 months, based on the conditions patients have.

Savings for these medications range from 40% to 75.8%, study results show.

Ticovac is the only FDA-approved vaccine against the TBE virus for individuals visiting or living in TBE endemic areas.

It is time to standardize to a single formulation to avoid mix-ups that can lead to adverse effects.

The expanded indication follows Lyumjev’s original approval in 2020 and offers an important new delivery mechanism for patients with diabetes.

The approval marks the first HIF-2α inhibitor therapy approved in the United States for some types of Von Hippel-Lindau disease-associated tumors.

Experts anticipate a return to high influenza rates as COVID-19 prevention measures decline.

Douglas Hoey, RPh, MBA, CEO of the National Community Pharmacists Association, addresses how the role of pharmacists, opportunities, and issues facing community pharmacies internationally compare to the experience of community pharmacists in the United States.

Approval sought for oportuzumab monatox-qqrs (Vicinium) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), which was previously granted priority review by the FDA.

The amount of green space surrounding children’s homes may impact the development of ADHD.

HDHPs require patients to pay for all care out of pocket until the plan’s deductible is reached, and only after this threshold does insurance start to cover medical costs.

The pandemic taught the pharmacy to provide a deeper level of personalized care and communication than in the past.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the FDA’s new guidance Project Optimus, which addresses issues relating to dose optimization in clinical trials assessing oncology drugs.

Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) was approved in July in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma following their first or subsequent relapse.

Vitamin D promotes calcium absorption in the gut and maintains adequate serum calcium and phosphate concentrations to enable normal bone mineralization and to prevent hypocalcemic tetany.

Anyone, even young people, can get infected, so the varicella or zoster vaccines offer the best prevention.

New treatments show promise for patients with KRAS G12C–mutated disease.

In the latest Student Cafe interview series, students from the University of Texas at Austin College of Pharmacy discussed the future of pharmacy after the COVID-19 pandemic.

The FDA recently authorized COVID-19 vaccine booster shots for immunocompromised individuals, who comprise about 3% of the US population.

Nicholas Mathews, co-founder of Stillwater Behavioral Health, discusses how pharmacists can respond to the identification of potentially problematic opioid prescription practices at sober-living facilities.

Analyzing how off-target antibodies may be undermining HIV vaccine prototypes allows for design improvements.

Trial is the first to suggest that targeting interleukin-4 and interleukin-13 can help address symptoms such as persistent itching and hives.